All In Biotech

Drug Trial Radar · NCT07112222

A Study of LM-350 in Subjects With Advanced Solid Tumours

A Phase I/II, First-in-Human (FIH), Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-350 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Aug 28, 2025

Primary completion

Jun 30, 2028

Study completion Jun 30, 2030

Sponsor

Lead sponsor
LaNova Medicines LimitedIndustry
Sponsor type
Industry
First posted
Aug 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

For Phase I Dose Escalation Stage, to assess the safety and tolerability of LM-350 in patients with advanced solid tumors,determine the maximum tolerated dose (MTD) or optimal biological dose (OBD), and explore the relationship between the biomarkers and the anti-tumor activity of LM-350. For Phase II Dose Expansion Stage, to assess the preliminary anti-tumor activity of LM-350 in patients with advanced solid tumors.

Conditions

  • Malignant Tumors

Interventions

  • LM-350 for injectionDrug

    Q3W,Intravenous Drip

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limitingtoxicity (DLT)Time frame: 78 weeks
  2. Incidence of Treatment-Emergent Adverse Events (AEs)Time frame: 78 weeks
  3. Incidence of serious adverse events (SAEs)Time frame: 78 weeks
  4. Temperature (Celsius)Time frame: 78 weeks
  5. Pulse in BPM(Beat per Minute)Time frame: 78 weeks
  6. Blood Pressure in mmHgTime frame: 78 weeks
  7. Weight in KgTime frame: 78 weeks
  8. Height in centimeterTime frame: 78 weeks
  9. Blood Routine examination -> Complete Blood CountTime frame: 78 weeks
  10. Urine Routine examination ->UrinalysisTime frame: 78 weeks
  11. Blood Biochemistry test -> Electrolytes and Metabolic ParametersTime frame: 78 weeks
  12. Coagulation function test-For the detection of Prothrombin time (PT), Activated partial thromboplastin time (APTT), International normalizedTime frame: 78 weeks
  13. Pregnancy testTime frame: 78 weeks
  14. Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentageTime frame: 78 weeks
  15. 12-lead electrocardiogram (ECG) in HRTime frame: 78 weeks
  16. 12-lead electrocardiogram (ECG) in RRTime frame: 78 weeks
  17. 12-lead electrocardiogram (ECG) in QRSTime frame: 78 weeks
  18. 12-lead electrocardiogram (ECG) in QTTime frame: 78 weeks
  19. 12-lead electrocardiogram (ECG) in QTcFTime frame: 78 weeks
  20. ECOG(Eastern Cooperative Oncology Group) scoreTime frame: 78 weeks
  21. Objective Response Rate (ORR)Time frame: 130 weeks

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Cancer Care Wollongong Pty Limited

    Wollongong, New South Wales, Australia · Recruiting

  • Cancer Research SA

    Adelaide, South Australia, Australia · Recruiting

  • Peninsula and South Eastern Haematology and Oncology Group

    Frankston, Victoria, Australia · Recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.